NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









CorFlow Therapeutics AG

CorFlow Therapeutics AG

Private
BaarHealthcare & Life Scienceshttps://corflow.com/

Last Round

Series B

Sep 9, 2024

Total Funding Raised

$58.2M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

CorFlow Therapeutics AG is a medical technology company that develops diagnostic and therapeutic devices for the treatment of microvascular obstruction in heart attack patients.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Medical Imaging, Clinical Trials

Business Model

B2B

Customer Profile

Hardware Sales, Services & Consulting

AI Layer

Application

Keywords

medical devicemicrovascular obstructionMVOpercutaneous coronary interventionPCIinterventional cardiologycardiac catheterizationcath labcontrolled flow infusionCoFISTEMIheart attack treatmentmedtechcardiovascular deviceclinical trial

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

CorFlow Therapeutics AG Comps

Public and private peers based on sector, stage, and business model.

CorFlow Therapeutics AG comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

CorFlow Therapeutics AG Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BSep 9, 2024
SeedSep 12, 2018

Key People

Founding team and executive leadership

Paul G. Mead

Chief Executive Officer And Board Member

Executive Team

Duraid Antone

COO CCO

Executive Team

CorFlow Therapeutics AG Investors

Notable investors and investment history

CorFlow Therapeutics AG investors
InvestorRounds
KOFA HealthcareSeries B
415 CapitalSeries B
Unorthodox VenturesSeries B
Panakès PartnersSeries B
Wellington PartnersSeries B
M&L HealthcareSeries B
M&L Healthcare InvestmentsSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 1, 2026

    Second generation CoFI system now in clinical trials.

  • May 6, 2025

    Rick Geoffrion stepped down as Chairman, replaced by Chris O'Connell.

CorFlow Therapeutics AG Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

CorFlow Therapeutics AG Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about CorFlow Therapeutics AG's valuation, stock price, and market status.

Firmographic Details

HeadquartersBaar
Employee Range38
Year Founded2016
Last FundingSep 9, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.